Hematology

Pegfilgrastim (Neulasta; Amgen) treats neutropenia that is caused by cancer medications and helps the bone marrow to create new white blood cells.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.

A patient with BPDCN finds her champion.

The accelerated approval comes after 48-week major molecular response rate data.

The new indications include pediatric individuals with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.

Courtney VanHouzen, PharmD shares insights about the community bispecific program at Munson Healthcare.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

The findings may offer patients treatment options beyond symptom palliation.

Zanubrutinib demonstrated sustained responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

These interim trial results support the ongoing phase 3 ITHACA trial.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

The discontinuation comes after a review of the medication by the European Medicines Agency which found that “the total number of deaths was higher than anticipated.”

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.